athenahealth splashes out $293m on mobile health firm Epocrates
This article was originally published in Clinica
Electronic health record firm athenahealth has bolstered its mobile health offering by agreeing to buy Epocrates, which specialises in mobile decision support software. The agreed price, of $11.75 per share or approximately $293 million in total, represents a 22% premium over Epocrates' closing share price of $9.62 on 4 January – it is also makes the deal athenahealth's biggest acquisition to date, according to Forbes.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.